- ：
- Unit Price：
- Quantity：
Original
-
Code：008195-001
Original
- Fosrenol Chewable Tablets 500mg：12tablets
- $106.99
Up to 3 pieces per person
10% discount for total amount over $100
shipping schedule : 5 to 10 working days after payment
warehouse：Japan1
Manufacturer ：Bayer Pharma
Brand ：Bayer Pharma
JAN Code：----
-
Description
-
Fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
-
Presentation
-
12 tablets
-
Feature
-
White, round, 18mm, bevelled-edge flat tablets debossed with 'S405/500' on one side.
-
Active Ingredients
-
Lanthanum carbonate hydrate 500mg
-
Effect/Efficacy
-
Fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (CAPD). Fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels ≥1.78 mmol/L in whom a low phosphate diet alone is insufficient to control serum phosphate levels.
-
Usage/Dosage
-
Fosrenol is for oral administration.
The tablets must be chewed completely and not swallowed whole. To aid with chewing the tablets may be crushed. Fosrenol oral powder can be used in patients who have difficulty chewing the tablets
Adults, including elderly (> 65 years)
Fosrenol should be taken with or immediately after food, with the daily dose divided between meals. Patients should adhere to recommended diets in order to control phosphate and fluid intake. Fosrenol is presented as a chewable tablet therefore avoiding the need to take additional fluid. Serum phosphate levels should be monitored and the dose of Fosrenol titrated every 2-3 weeks until an acceptable serum phosphate levels is reached, with regular monitoring thereafter.
Control of serum phosphate level has been demonstrated at doses starting from 750 mg per day. The maximum dose studied in clinical trials, in a limited number of patients, is 3750mg Patients who respond to lanthanum therapy, usually achieve acceptable serum phosphate levels at doses of 1500 – 3000 mg lanthanum per day.
-
Cautions
-
Talk to your doctor or pharmacist before taking Fosrenol if you know that you have, or have had, any of the following:
• stomach or intestinal cancer
• inflammatory bowel disease including ulcerative colitis or Crohn’s
disease
• abdominal surgery, or infection or inflammation of the abdomen/
bowel (peritonitis)
• stomach or intestinal ulcers
• blockage of the intestine or slow motility (movement) in the intestine
(e.g. constipation and stomach complications due to diabetes)
•ｒeduced liver or kidney function.
The tablets must be chewed completely and not swallowed whole. To aid with chewing, the tablets may be crushed. Additional fluid is not necessary.
-
Contraindication
-
The most commonly reported adverse drug reactions, with the exception of headache and allergic skin reactions, are gastrointestinal in nature; these are minimised by taking Fosrenol with food and generally abated with time with continued dosing (see section 4.2).
The following convention was used for frequency of adverse drug reactions: Very common (≥1/10); Common (≥1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥1/10,000 to < 1/1,000); Very rare (< 1/10,000), not known (cannot be estimated from the available data).
